Summary
Global Markets Directs, Erosive Oral Lichen Planus - Pipeline Review, H1 2012, provides an overview of the Erosive Oral Lichen Planus therapeutic pipeline. This report provides information on the therapeutic development for Erosive Oral Lichen Planus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Erosive Oral Lichen Planus. Erosive Oral Lichen Planus - Pipeline Review, H1 2012 is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Erosive Oral Lichen Planus.
- A review of the Erosive Oral Lichen Planus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Table of contents:
List of Tables 13
List of Figures 18
Introduction 19
Global Markets Direct Report Coverage
19
Pancreatic Cancer Overview 20
Therapeutics Development 21
An Overview of Pipeline Products for Pancreatic Cancer 21
Pancreatic Cancer Therapeutics under Development by Companies 23
Pancreatic Cancer Therapeutics under Investigation by Universities/Institutes 35
Late Stage Products 47
Comparative Analysis 47
Mid Clinical Stage Products 48
Comparative Analysis 48
Early Clinical Stage Products 49
Comparative Analysis 49
Discovery and Pre-Clinical Stage Products 50
Comparative Analysis 50
Pancreatic Cancer Therapeutics Products under Development by Companies 51
Pancreatic Cancer Therapeutics Products under Investigation by Universities/Institutes 65
Companies Involved in Pancreatic Cancer Therapeutics Development 90
Bristol-Myers Squibb Company 90
Johnson Johnson 91
Boehringer Ingelheim GmbH 92
List of Figures
List of Tables are also include.
For more related Reports Plz follow The link:
Pipeline Review, H1 2012
http://www.aarkstore.com/search/viewresults.asp?search=Pipeline Review, H1 2012PubId=pagenum=1
Erosive Oral Lichen Planus Pipeline Review, H1 2012
Pancreatic Cancer Pipeline Review, H1 2012
Metastatic Hormone Refractory Prostate Cancer Pipeline Review, H1 2012
Myasthenia Gravis Pipeline Review, H1 2012
Dental Plaque Pipeline Review, H1 2012
Esophagitis Pipeline Review, H1 2012
Retinitis Pigmentosa (Retinitis) Pipeline Review, H1 2012
Cellulite Pipeline Review, H1 2012
HIV Pain Pipeline Review, H1 2012
Tropical Spastic Paraparesis Pipeline Review, H1 2012
Search More Reports Related to This Category :
Pharmaceuticals and Healthcare
http://www.aarkstore.com/search/viewresults.asp?search=Pharmaceuticals and HealthcarePubId=pagenum=1
For More details Plz do contact :
Aarkstore Enterprise
Lavanya
Phone:08149852585
Email: enquiry@aarkstore.com
